Here's why Regeneron (REGN) and Bayer's (BAYRY) fast growing Eylea for AMD is on target to eclipse $2 billion in global sales this year. Few drugs become multi-billion blockbusters, but those that do ...

Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the publication of two important clinical studies supporting the effectiveness of ...

Eylea is a brand-name biologic prescription medication containing the active ingredient aflibercept. Generic versions of biologic drugs are called biosimilars. Due to the complex manufacturing process ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...

Biosimilars are coming for Regeneron and Bayer’s Eylea’s crown, but the blockbuster reign is under no immediate threat of being overthrown. That’s according to a new joint analysis from analysts with ...

Regeneron is looking for ways to keep star med Eylea growing well into the future--and pacing ahead of the competition. But it looks like a combination with compound rinucumab won’t be one of them.

Bayer’s retinal disease treatment Eylea (aflibercept) is set for an extended treatment interval, a label extension that could give the drug an advantage over rival Roche’s Vabysmo (faricimab). A ...

Regeneron announced that patients taking an 8 mg high-dose version of its ophthalmology drug Eylea (already approved at a 2 mg dose) were largely able to maintain longer dosing intervals than the ...

Few drugs become multi-billion blockbusters, but those that do usually have similar characteristics. They treat big, and growing patient populations; they don't compete with too many other drugs (and ...